PFMOSF
CYTK icon

Philadelphia Financial Management of San Francisco’s Cytokinetics CYTK Stock Holding History

Philadelphia Financial Management of San Francisco’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,523
Closed -$2.17M – 66
2025
Q3 		$2.17M Buy
+39,523
New +$1.63M 0.24% 55

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Philadelphia Financial Management of San Francisco's CYTK Position: Q4 2025 in Review

Philadelphia Financial Management of San Francisco sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 39,523 shares — an estimated $2.17M sold.

Philadelphia Financial Management of San Francisco first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $2.17M in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Philadelphia Financial Management of San Francisco reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Philadelphia Financial Management of San Francisco sold 39,523 Cytokinetics shares in Q4 2025, an estimated $2.17M.
  • Philadelphia Financial Management of San Francisco first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
  • Philadelphia Financial Management of San Francisco's Cytokinetics position peaked at $2.17M in Q3 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Philadelphia Financial Management of San Francisco's 13F filing for Q4 2025, filed 17 Feb 2026.